Abstract:
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Abstract:
Fc regions comprising modification to increase the affinity of association between the Fc region and TRIM21 are disclosed. Also disclosed are constituent polypeptides of such Fc regions, antigen-binding molecules and immunogens comprising such Fc regions, and nucleic acids encoding and methods using such Fc regions, antigen-binding molecules and immunogens.
Abstract:
Antibodies and fragments thereof which bind to peptide-MHC complexes are described. In particular, an antibody binding to a peptide-MHC complex comprising a peptide of p53 and a MHC Class I molecule comprising α-chain encoded by an HLA-A*24 allele is claimed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods of treating, preventing and diagnosing cancers using the same.
Abstract:
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Abstract:
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Abstract:
Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Abstract:
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Abstract:
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Abstract:
The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.
Abstract:
Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.